ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Waimei Si

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9026-5149; OpenAlex author ID A5036859860. Sources: OpenAlex.

Their work

Papers: 5 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 15

Papers, trials and grants by year

2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 5

Luteolin Triggers Pyroptosis in Pancreatic Ductal Adenocarcinoma by Inhibiting Mitochondrial Fission through the RAS/ERK/DRP1 Pathway. Co-author DOI 10.1142/s0192415x26500606 ↗
Bufalin Suppresses Pancreatic Ductal Adenocarcinoma Through ER Stress-Ferroptosis Crosstalk Associated with IP3R-Linked Ca2+ Dysregulation and ATF3/SLC7A11 Reg… Co-author DOI 10.3390/ijms27104373 ↗
Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.phymed.2025.157048 ↗
Modified Sijunzi Decoction Inhibits Pancreatic Cancer Progression and Improves Immune Suppression: Network Pharmacology and Experimental Validation. Co-author DOI 10.2147/dddt.s520390 ↗
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal aden… Co-author DOI 10.1038/s41392-024-02052-3 ↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xin Li · 4 shared papers, 2025–2026 · strength 1.18
Peiwen Yang · 4 shared papers, 2025–2026 · strength 1.18
Yuan Zhang · 3 shared papers, 2025–2026 · strength 0.87
He Ba · 3 shared papers, 2025–2026 · strength 0.87
Linjie Ruan · 3 shared papers, 2025–2026 · strength 0.87
Zhen Chen · 2 shared papers, 2025–2026 · strength 0.58
- Paper Luteolin Triggers Pyroptosis in Pancreatic Ductal Adenocarcinoma by Inhibiting Mitochondrial Fission through the RAS/ER… DOI 10.1142/s0192415x26500606 ↗
- Paper Modified Sijunzi Decoction Inhibits Pancreatic Cancer Progression and Improves Immune Suppression: Network Pharmacology… DOI 10.2147/dddt.s520390 ↗
Lixia Yi · 2 shared papers, 2024–2026 · strength 0.49
- Paper Luteolin Triggers Pyroptosis in Pancreatic Ductal Adenocarcinoma by Inhibiting Mitochondrial Fission through the RAS/ER… DOI 10.1142/s0192415x26500606 ↗
- Paper Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliar… DOI 10.1038/s41392-024-02052-3 ↗
Zhen Chen · 1 shared paper, 2026 · strength 0.32
- Paper Bufalin Suppresses Pancreatic Ductal Adenocarcinoma Through ER Stress-Ferroptosis Crosstalk Associated with IP3R-Linked… DOI 10.3390/ijms27104373 ↗
Xiaoyan Zhu · 1 shared paper, 2026 · strength 0.32
- Paper Bufalin Suppresses Pancreatic Ductal Adenocarcinoma Through ER Stress-Ferroptosis Crosstalk Associated with IP3R-Linked… DOI 10.3390/ijms27104373 ↗
Zhen Chen · 1 shared paper, 2025 · strength 0.28
- Paper Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcin… DOI 10.1016/j.phymed.2025.157048 ↗
Zhouyu Ning · 1 shared paper, 2024 · strength 0.18
- Paper Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliar… DOI 10.1038/s41392-024-02052-3 ↗
Jing Xie · 1 shared paper, 2024 · strength 0.18
- Paper Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliar… DOI 10.1038/s41392-024-02052-3 ↗
Yifan Yang · 1 shared paper, 2024 · strength 0.18
- Paper Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliar… DOI 10.1038/s41392-024-02052-3 ↗
Xiaoyan Zhu · 1 shared paper, 2024 · strength 0.18
- Paper Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliar… DOI 10.1038/s41392-024-02052-3 ↗
Zhiqiang Meng · 1 shared paper, 2024 · strength 0.18
- Paper Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliar… DOI 10.1038/s41392-024-02052-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.